Pharmacokinetic properties of a novel inosine analog, 40-cyano-20-deoxyinosine, after oral administration in rats

Mai Hashimoto, Kazuaki Taguchi, Takako Ishiguro, Satoru Kohgo, Shuhei Imoto, Keishi Yamasaki, Hiroaki Mitsuya, Masaki Otagiri

研究成果: Article

抄録

40-cyano-20-deoxyinosine (SK14-061a), a novel nucleoside analog based on inosine, has antiviral activity against the human immunodeficiency virus type 1 that has the ability to acquire resistance against many types of reverse transcriptase inhibitors based on nucleosides. The aim of this study was to investigate the pharmacokinetics studies after its oral administration to rats. For this purpose, we first developed and validated an analytical method for quantitatively determining SK14-061a levels in biological samples by a UPLC system interfaced with a TOF-MS system. A rapid, simple and selective method for the quantification of SK14-061a in biological samples was established using liquid chromatography mass spectrometry (LC-MS) with solid phase extraction. The pharmacokinetic properties of SK14-061a in rats after oral administration were then evaluated using this LC-MS method. SK14-061a was found to be relatively highly bioavailable, is rapidly absorbed from the intestinal tract, and is then mainly distributed to the liver and then ultimately excreted via the urine in an unchanged form. Furthermore, the simultaneous administration of SK14-061a with the nucleoside analog, entecavir, led to a significant alteration in the pharmacokinetics of SK14-061a. These results suggest that the SK14-061a has favorable pharmacokinetic properties with a high bioavailability with the potential for use in oral pharmaceutical formulations, but drug-drug interactions should also be considered.

元の言語English
記事番号e0198636.
ジャーナルPLoS One
13
発行部数6
DOI
出版物ステータスPublished - 2018 6 1
外部発表Yes

Fingerprint

Inosine
Pharmacokinetics
oral administration
pharmacokinetics
Oral Administration
Rats
nucleosides
Nucleosides
rats
Liquid chromatography
Liquid Chromatography
liquid chromatography
Mass spectrometry
Mass Spectrometry
drug formulations
Drug interactions
mass spectrometry
drug interactions
Drug Compounding
Reverse Transcriptase Inhibitors

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Agricultural and Biological Sciences(all)

これを引用

Hashimoto, M., Taguchi, K., Ishiguro, T., Kohgo, S., Imoto, S., Yamasaki, K., ... Otagiri, M. (2018). Pharmacokinetic properties of a novel inosine analog, 40-cyano-20-deoxyinosine, after oral administration in rats. PLoS One, 13(6), [e0198636.]. https://doi.org/10.1371/journal.pone.0198636

Pharmacokinetic properties of a novel inosine analog, 40-cyano-20-deoxyinosine, after oral administration in rats. / Hashimoto, Mai; Taguchi, Kazuaki; Ishiguro, Takako; Kohgo, Satoru; Imoto, Shuhei; Yamasaki, Keishi; Mitsuya, Hiroaki; Otagiri, Masaki.

:: PLoS One, 巻 13, 番号 6, e0198636., 01.06.2018.

研究成果: Article

Hashimoto, M, Taguchi, K, Ishiguro, T, Kohgo, S, Imoto, S, Yamasaki, K, Mitsuya, H & Otagiri, M 2018, 'Pharmacokinetic properties of a novel inosine analog, 40-cyano-20-deoxyinosine, after oral administration in rats', PLoS One, 巻. 13, 番号 6, e0198636.. https://doi.org/10.1371/journal.pone.0198636
Hashimoto, Mai ; Taguchi, Kazuaki ; Ishiguro, Takako ; Kohgo, Satoru ; Imoto, Shuhei ; Yamasaki, Keishi ; Mitsuya, Hiroaki ; Otagiri, Masaki. / Pharmacokinetic properties of a novel inosine analog, 40-cyano-20-deoxyinosine, after oral administration in rats. :: PLoS One. 2018 ; 巻 13, 番号 6.
@article{29f4ee60254c4b66888b85166af32a85,
title = "Pharmacokinetic properties of a novel inosine analog, 40-cyano-20-deoxyinosine, after oral administration in rats",
abstract = "40-cyano-20-deoxyinosine (SK14-061a), a novel nucleoside analog based on inosine, has antiviral activity against the human immunodeficiency virus type 1 that has the ability to acquire resistance against many types of reverse transcriptase inhibitors based on nucleosides. The aim of this study was to investigate the pharmacokinetics studies after its oral administration to rats. For this purpose, we first developed and validated an analytical method for quantitatively determining SK14-061a levels in biological samples by a UPLC system interfaced with a TOF-MS system. A rapid, simple and selective method for the quantification of SK14-061a in biological samples was established using liquid chromatography mass spectrometry (LC-MS) with solid phase extraction. The pharmacokinetic properties of SK14-061a in rats after oral administration were then evaluated using this LC-MS method. SK14-061a was found to be relatively highly bioavailable, is rapidly absorbed from the intestinal tract, and is then mainly distributed to the liver and then ultimately excreted via the urine in an unchanged form. Furthermore, the simultaneous administration of SK14-061a with the nucleoside analog, entecavir, led to a significant alteration in the pharmacokinetics of SK14-061a. These results suggest that the SK14-061a has favorable pharmacokinetic properties with a high bioavailability with the potential for use in oral pharmaceutical formulations, but drug-drug interactions should also be considered.",
author = "Mai Hashimoto and Kazuaki Taguchi and Takako Ishiguro and Satoru Kohgo and Shuhei Imoto and Keishi Yamasaki and Hiroaki Mitsuya and Masaki Otagiri",
year = "2018",
month = "6",
day = "1",
doi = "10.1371/journal.pone.0198636",
language = "English",
volume = "13",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "6",

}

TY - JOUR

T1 - Pharmacokinetic properties of a novel inosine analog, 40-cyano-20-deoxyinosine, after oral administration in rats

AU - Hashimoto, Mai

AU - Taguchi, Kazuaki

AU - Ishiguro, Takako

AU - Kohgo, Satoru

AU - Imoto, Shuhei

AU - Yamasaki, Keishi

AU - Mitsuya, Hiroaki

AU - Otagiri, Masaki

PY - 2018/6/1

Y1 - 2018/6/1

N2 - 40-cyano-20-deoxyinosine (SK14-061a), a novel nucleoside analog based on inosine, has antiviral activity against the human immunodeficiency virus type 1 that has the ability to acquire resistance against many types of reverse transcriptase inhibitors based on nucleosides. The aim of this study was to investigate the pharmacokinetics studies after its oral administration to rats. For this purpose, we first developed and validated an analytical method for quantitatively determining SK14-061a levels in biological samples by a UPLC system interfaced with a TOF-MS system. A rapid, simple and selective method for the quantification of SK14-061a in biological samples was established using liquid chromatography mass spectrometry (LC-MS) with solid phase extraction. The pharmacokinetic properties of SK14-061a in rats after oral administration were then evaluated using this LC-MS method. SK14-061a was found to be relatively highly bioavailable, is rapidly absorbed from the intestinal tract, and is then mainly distributed to the liver and then ultimately excreted via the urine in an unchanged form. Furthermore, the simultaneous administration of SK14-061a with the nucleoside analog, entecavir, led to a significant alteration in the pharmacokinetics of SK14-061a. These results suggest that the SK14-061a has favorable pharmacokinetic properties with a high bioavailability with the potential for use in oral pharmaceutical formulations, but drug-drug interactions should also be considered.

AB - 40-cyano-20-deoxyinosine (SK14-061a), a novel nucleoside analog based on inosine, has antiviral activity against the human immunodeficiency virus type 1 that has the ability to acquire resistance against many types of reverse transcriptase inhibitors based on nucleosides. The aim of this study was to investigate the pharmacokinetics studies after its oral administration to rats. For this purpose, we first developed and validated an analytical method for quantitatively determining SK14-061a levels in biological samples by a UPLC system interfaced with a TOF-MS system. A rapid, simple and selective method for the quantification of SK14-061a in biological samples was established using liquid chromatography mass spectrometry (LC-MS) with solid phase extraction. The pharmacokinetic properties of SK14-061a in rats after oral administration were then evaluated using this LC-MS method. SK14-061a was found to be relatively highly bioavailable, is rapidly absorbed from the intestinal tract, and is then mainly distributed to the liver and then ultimately excreted via the urine in an unchanged form. Furthermore, the simultaneous administration of SK14-061a with the nucleoside analog, entecavir, led to a significant alteration in the pharmacokinetics of SK14-061a. These results suggest that the SK14-061a has favorable pharmacokinetic properties with a high bioavailability with the potential for use in oral pharmaceutical formulations, but drug-drug interactions should also be considered.

UR - http://www.scopus.com/inward/record.url?scp=85048149127&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85048149127&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0198636

DO - 10.1371/journal.pone.0198636

M3 - Article

C2 - 29874291

AN - SCOPUS:85048149127

VL - 13

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 6

M1 - e0198636.

ER -